|Chemical and physical data|
|Molar mass||441.484 g·mol−1|
|3D model (JSmol)|
LASSBio-881 is a drug which acts as both a non-selective partial agonist of the CB1 and CB2 cannabinoid receptors, and also as an antagonist of the TRPV1 receptor, as well as having antioxidant effects. It has potent anti-inflammatory and anti-hyperalgesic effects in animal studies.
- has an identical structure sans the nitro FG.
- Duarte CD, Tributino JL, Lacerda DI, Martins MV, Alexandre-Moreira MS, Dutra F, et al. (March 2007). "Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors". Bioorganic & Medicinal Chemistry. 15 (6): 2421–33. doi:10.1016/j.bmc.2007.01.013. PMID 17275312.
- Tributino JL, Santos ML, Mesquita CM, Lima CK, Silva LL, Maia RC, et al. (April 2010). "LASSBio-881: an N-acylhydrazone transient receptor potential vanilloid subfamily type 1 antagonist orally effective against the hypernociception induced by capsaicin or partial sciatic ligation". British Journal of Pharmacology. 159 (8): 1716–23. doi:10.1111/j.1476-5381.2010.00672.x. PMC 2925494. PMID 20401963.